Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "179.50",
    "chg": 10.5,
    "chgp": "6.21%",
    "dir": 1,
    "prev_price": "169.00",
    "mcapval": "1,200.68 Cr",
    "mcap": "Small Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE048B01035",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "99.31 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/jagsonpal-pharma-134241-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Jagsonpal Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-jagsonpal-pharma-technically-bullish-or-bearish-3739975",
        "imagepath": "",
        "date": "2025-12-02 08:22:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Overview</strong></p>\n<p>As of 1 December 2025, Jagsonpal Pharma’s overall technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle shift indicates that while the stock remains under pressure, the intensity of selling momentum has somewhat eased. The change suggests that the market may be digesting recent developments and could be preparing for a potential stabilisation or reversal, though confirmation is yet to be seen.</p>\n<p><strong>Key Technical Indicators</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish signal on the weekly timeframe, while the monthly MACD is mildly bearish. This divergence implies that short-term momentum remains weak, but longer-..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3739878",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/JagsonpalPharma_technicaldot_3739878.png",
        "date": "2025-12-02 08:00:50",
        "description": "Jagsonpal Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. Recent data reveals a transition from a bearish stance to a mildly bearish trend, with key technical parameters such as MACD, RSI, and moving averages signalling a cautious outlook for the stock within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Jagsonpal Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3737212",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/JagsonpalPharma_mojoScore_3737212.png",
        "date": "2025-11-30 10:24:23",
        "description": "Jagsonpal Pharma has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of valuation concerns, technical indicators, and financial trends. This adjustment comes despite the company’s notable profit growth and ongoing challenges in market performance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Jagsonpal Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-jagsonpal-pharma-fallingrising-3721919",
        "imagepath": "",
        "date": "2025-11-22 00:38:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Jagsonpal Pharma’s stock has been on a downward trajectory over the past week, falling 4.54% while the Sensex gained 0.79% in the same period. The trend extends over longer horizons, with the stock declining 9.40% in the last month and 15.07% over the past year, contrasting sharply with the Sensex’s 10.47% gain during that timeframe. Year-to-date, the stock is down 17.78%, whereas the benchmark index has risen 9.08%. This persistent underperformance signals investor reluctance to back the stock despite broader market gains.</p>\n<p>On the day in question, the stock underperformed its sector by 1.79%, hitting an intraday low of ₹197.50, just 3.48% above its 52-week low of ₹194. The share price has now fallen for three consecutive sess..."
      },
      {
        "title": "Why is Jagsonpal Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-jagsonpal-pharma-fallingrising-3686892",
        "imagepath": "",
        "date": "2025-11-10 21:47:45",
        "description": "As of 10-Nov, Jagsonpal Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 213.20, which reflects a decrease of 2.9 or 1.34%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 5.64% over the past week. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite the company declaring positive results for the last six consecutive quarters, including a significant increase in operating profit, the stock's valuation appears expensive with a Price to Book Value of 5.9. Furthermore, the lack of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the stock's current price.\n\nIn the broader market context, the stock has significantly underperformed compared to the benchmark, with a return of -10.03% over the past year, while the market ..."
      }
    ],
    "total": 206,
    "sid": "134241",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "27-Jan-2026",
      "details": "Earnings Call Transcript for meeting held on 22 January 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "22-Jan-2026",
      "details": "Pursuant to Regulation 47 of SEBI (LODR) 2015 please find enclosed copies of advertisement published on January 22 2026 in Business Standard (English) and Business Standard (Hindi) newspaper providing extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "22-Jan-2026",
      "details": "In continuation to our earlier intimation dated January 15 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q3 FY26 Earnings Conference Call held on January 22 2026 at 5:00 P.M. for discussion of Q3 FY26 Financial Results is available on the Companys website at below link: https://www.jagsonpal.com/investor-relations/earning-calls. We request you to take the above on record.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>125%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Jagsonpal Pharma technically bullish or bearish?

2025-12-02 08:22:55

Technical Trend Overview As of 1 December 2025, Jagsonpal Pharma’s overall technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle shift indicates that while the stock remains under pressure, the intensity of selling momentum has somewhat eased. The change suggests that the market may be digesting recent developments and could be preparing for a potential stabilisation or reversal, though confirmation is yet to be seen. Key Technical Indicators Examining the Moving Average Convergence Divergence (MACD), a widely followed momentum indicator, reveals a bearish signal on the weekly timeframe, while the monthly MACD is mildly bearish. This divergence implies that short-term momentum remains weak, but longer-...

Jagsonpal Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:00:50

Jagsonpal Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of market indicators. Recent data reveals a transition from a bearish stance to a mildly bearish trend, with key technical parameters such as MACD, RSI, and moving averages signalling a cautious outlook for the stock within the Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals

2025-11-30 10:24:23

Jagsonpal Pharma has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of valuation concerns, technical indicators, and financial trends. This adjustment comes despite the company’s notable profit growth and ongoing challenges in market performance within the Pharmaceuticals & Biotechnology sector.

Why is Jagsonpal Pharma falling/rising?

2025-11-22 00:38:31

Recent Price Movement and Market Comparison Jagsonpal Pharma’s stock has been on a downward trajectory over the past week, falling 4.54% while the Sensex gained 0.79% in the same period. The trend extends over longer horizons, with the stock declining 9.40% in the last month and 15.07% over the past year, contrasting sharply with the Sensex’s 10.47% gain during that timeframe. Year-to-date, the stock is down 17.78%, whereas the benchmark index has risen 9.08%. This persistent underperformance signals investor reluctance to back the stock despite broader market gains. On the day in question, the stock underperformed its sector by 1.79%, hitting an intraday low of ₹197.50, just 3.48% above its 52-week low of ₹194. The share price has now fallen for three consecutive sess...

Why is Jagsonpal Pharma falling/rising?

2025-11-10 21:47:45

As of 10-Nov, Jagsonpal Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 213.20, which reflects a decrease of 2.9 or 1.34%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 5.64% over the past week. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite the company declaring positive results for the last six consecutive quarters, including a significant increase in operating profit, the stock's valuation appears expensive with a Price to Book Value of 5.9. Furthermore, the lack of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the stock's current price. In the broader market context, the stock has significantly underperformed compared to the benchmark, with a return of -10.03% over the past year, while the market ...

View All News